Filing summary
Entity and period: The supplied filing is Immudyne, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015, not a filing identified as LifeMD, Inc. Investors should verify the issuer before relying on this summary.
Business context and financial results
Immudyne develops, manufactures, and sells yeast beta-glucan immune-support products for oral and topical use. It sells through healthcare professionals, distributors, and direct-to-consumer channels.
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Sales | $288,277 | $192,429 |
| Gross profit / margin | $214,061 / 74% | $143,339 / 74% |
| Operating income (loss) | $7,834 | ($177,638) |
| Net income (loss) | $1,666 | ($140,939) |
| Operating cash flow | ($70,187) | ($6,647) |
| Cash at quarter end | $70,051 | $36,409 |
Sales increased 50% year over year, which management attributed primarily to increased product demand. Cost of sales rose 51%, broadly in line with sales growth, while gross margin remained 74%. Operating expenses fell 36% to $206,227, reflecting lower compensation, professional fees, and general and administrative expenses. Net income was only $1,666, and the reported basic and diluted earnings per share rounded to $0.00.
Liquidity, debt, and balance sheet
At March 31, 2015, current assets were $186,961 and current liabilities were $343,398, implying negative working capital of $156,437 and a current ratio of approximately 0.5. Total assets were $216,466; total liabilities were $352,298; and stockholders’ deficit was $135,832. Cash declined by $5,444 during the quarter as operating outflows exceeded financing inflows.
The company reported $91,943 of notes payable on its balance sheet. The notes describe a $100,000 short-term commercial loan, repayments, and officer/director advances; the notes-payable activity table gives a quarter-end total of $91,743, which conflicts with the balance sheet. The commercial loan required 252 daily payments of $492 beginning January 12, 2015. Interest expense was $10,468, versus $478 in Q1 2014.
Outlook, risks, and notable items
- Going concern and financing: The filing states that the accumulated deficit was approximately $8.5 million and that negative cash flows and limited working capital raise substantial doubt about the company’s ability to continue as a going concern. Management expected available resources, including the Q1 loan, to fund operations through the first half of 2015, but anticipated needing additional capital for the remainder of the year through higher sales, equity issuance, or debt. No assurance was given that financing would be available on acceptable terms.
- Customer concentration: One customer represented 84% of Q1 2015 sales (92% in Q1 2014) and 100% of receivables at both March 31, 2015 and December 31, 2014. A second customer accounted for 12% of Q1 2015 sales.
- Related royalty obligation: A royalty agreement requires 8% of sales of certain skin-care products, up to a stated cap. Accrued amounts under the agreement were $151,986; the remaining commitment was approximately $1,000. The president has a 60% interest in the royalties and had voluntarily deferred payment without interest.
- Management plans and risks: Management prioritized sales growth and anticipated increased marketing and advertising costs. It cited risks including insufficient capital, dependence on experienced personnel, intellectual-property protection, and possible changes in government regulation. The filing did not provide quantified revenue or earnings guidance.
- Controls: Management concluded disclosure controls and procedures were ineffective due to material weaknesses involving segregation of duties, written accounting and reporting procedures, computer-system security and disaster recovery, and the absence of a written whistleblower policy. Remediation was conditional on sufficient funding.
- Legal matters: Management said it was not aware of current proceedings expected to have a material adverse effect. The filing also describes prior patent-related settlements; the final $25,000 license installment was received in Q1 2014.
Most important facts to verify
- Confirm that Immudyne, Inc., rather than LifeMD, Inc., is the intended issuer and that the reporting period is Q1 2015.
- Reconcile the $91,943 balance-sheet notes payable with the $91,743 total in the notes-payable activity table.
- Review the company’s ability to secure funding, meet near-term obligations, and continue as a going concern.
- Assess the effects of customer concentration and collection risk, given the single customer’s share of sales and receivables.
- Track remediation of the disclosed material weaknesses and the related-party royalty accrual and payment deferrals.